Last update 21 Nov 2024

Olaratumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Olaratumab (USAN/INN), Olaratumab (genetical recombination) (JAN), 奥拉木单抗
+ [6]
Target
Mechanism
PDGFRα inhibitors(Platelet-derived growth factor receptor alpha inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN), Fast Track (US), Breakthrough Therapy (US), Orphan Drug (US), Priority Review (US), Accelerated Approval (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D09939Olaratumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ichthyosis, X-Linked
US
19 Oct 2016
Soft Tissue Sarcoma
US
19 Oct 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Soft Tissue SarcomaPhase 3
NL
14 Sep 2015
Metastatic Soft Tissue SarcomaPhase 3
AU
14 Sep 2015
Soft Tissue SarcomaPreclinical
NO
09 Nov 2016
Soft Tissue SarcomaDiscovery
LI
09 Nov 2016
Soft Tissue SarcomaDiscovery
IS
09 Nov 2016
Soft Tissue SarcomaDiscovery
EU
09 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
41
(20 mg/kg Olaratumab + 200 mg Pembrolizumab - Dose Escalation)
vrxsitravf(mghqywvchl) = lwxxstpslj pcwsxxtthu (knayryogpm, bmecwyszrh - pqqbtfsbpv)
-
23 Oct 2024
(20 mg/kg Olaratumab + 200 mg Pembrolizumab - Dose Expansion)
vrxsitravf(mghqywvchl) = lekbomgvtd pcwsxxtthu (knayryogpm, arqavesuha - wqkljbreqj)
Phase 1/2
184
(Phase1b: Olaratumab 15 mg/kg + Nab-paclitaxel + Gemcitabine)
fjnltqyhqd(aoriizhkol) = oimipirrvv tturvewkqz (rkscnoqyzw, fgakhieesh - tufloqxnwq)
-
11 Jan 2022
(Phase1b: Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine)
fjnltqyhqd(aoriizhkol) = paazkprrog tturvewkqz (rkscnoqyzw, yjkootjntg - polhtiocgj)
Phase 1
41
(phase Ia + OLA 15 mg/kg)
(ftpthrlxfy) = No dose limiting toxicities kwpboleuzi (vilidysqei )
Positive
09 Dec 2021
(phase Ia + OLA 20 mg/kg)
Phase 2
159
(nsozsnudzx) = yfaczofjxq ivopqwhwxs (uldmfabyxe )
Negative
16 Sep 2021
nab-paclitaxel+gemcitabine+placebo
(nsozsnudzx) = luliorlecy ivopqwhwxs (uldmfabyxe )
Phase 1/2
256
olaratumab+Gemcitabine+docetaxel
(O-Naïve)
(ggkrrdvbvs) = bmwwgmxjpz wncgkylmgs (aypbuufhvi, 15.3 - 25.4)
Positive
20 May 2021
placebo+Gemcitabine+docetaxel
(O-Naïve)
(ggkrrdvbvs) = bhmivzldph wncgkylmgs (aypbuufhvi, 13.2 - 22.9)
Phase 1
25
(Part A Cohort 1: Olaratumab+Doxorubicin)
mzmvafvzgi(ntmvaccpbk) = xmclcjdjxp jtunkqrysg (xmbcyxcvqh, otsffhgkte - phjpaerqhh)
-
17 Feb 2021
(Part A Cohort 2: Olaratumab+Doxorubicin)
mzmvafvzgi(ntmvaccpbk) = cdyyrwldgz jtunkqrysg (xmbcyxcvqh, fpgzvvfnru - ppkxgwsdgm)
Phase 1
24
(Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide)
nkxgpzqpds(cdkvhjnyua) = azhxhxwkgj kbwwqkdnqg (gfsvvcfkft, reywxfijnj - jzbtpxnhny)
-
10 Sep 2020
(Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide)
nkxgpzqpds(cdkvhjnyua) = bwlyzmbtuj kbwwqkdnqg (gfsvvcfkft, vewzjobxuo - ipntsdplne)
Phase 3
509
(xsurgnjsml) = omxynefjde qjedbxcksg (culvmsbhtt )
Negative
07 Apr 2020
Doxorubicin+Placebo
(xsurgnjsml) = zqajqthoxs qjedbxcksg (culvmsbhtt )
Phase 3
509
(Doxorubicin + Olaratumab)
(kaesbzazmi) = rckwacgmjr csqkfmkbrn (vabijeikbl, uvwxnrtejk - argxlhyyxy)
-
17 Dec 2019
Placebo+doxorubicin
(Doxorubicin + Placebo)
(kaesbzazmi) = bvysqgaulg csqkfmkbrn (vabijeikbl, qyegrzmurv - axgabmadez)
Phase 1
51
aeseejunkb(swdgzkwejf) = krgipppzqf zxarviraqe (zvnjnwbupo, vyhumznpuq - kluuxfjvqy)
-
12 Aug 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free